This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carter, H. B. Articles by Walsh, P. C. Search for Related Content PubMed PubMed Citation Articles by Carter, H. B. Articles by Walsh, P. C.

Estimation of Prostatic Growth Using Serial Prostate-specific Antigen Measurements in Men with and without Prostate Disease¹

Departments of Urology (H. B. C., P. C. W.) and Laboratory Medicine (D. W. C.), The Johns Hopkins University School of Medicine and The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21205, and National Institute on Aging, Gerontology Research Center, Baltimore, Maryland (C. H. M., J. D. P., L. J. B., C. C. P., E. J. M., J. L. F.)

Prostate growth curves were estimated from serial prostate-specific antigen (PSA) measurements on frozen sera in three groups of men: (a) 16 men with no prostatic disease by urological history and examination; (b) 20 men with a histological diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and (c) 18 men with a histological diagnosis of prostate cancer. The median number of repeated PSA measurements over an 8- to 26-yr period prior to histological diagnosis or exclusion of prostate disease was eight and 11 for noncancer and cancer subjects, respectively. Predicted rates of change in PSA (PSA velocity) were linear and curvilinear for control and BPH subjects, respectively. Subjects with cancer demonstrated both a linear and an exponential phase of PSA velocity. Based on time to double PSA, we estimated the epithelial doubling time for men without prostate disease to range from 54 ± 13 yr at age 40 to 84 ± 13 yr at age 70. For men with BPH, doubling times ranged from 2 ± 13 yr at age 40 to 17 ± 5 yr at age 85. Subjects with local/regional and advanced/metastatic cancer had similar PSA doubling times of 2.4 ± 0.6 yr and 1.8 ± 0.2 yr, respectively. These data are consistent with what is known about prostatic growth with age in men without prostate disease and BPH, and the kinetics of prostate cancer growth. Estimates of prostatic growth rate from changes in PSA may be useful clinically in management of men with prostate disease.

¹ Research was conducted by the National Institute on Aging Intramural Research Program.

² To whom requests for reprints should be addressed.

Received 2/17/92. Accepted 4/ 7/92.

This article has been cited by other articles:

				R. D. Etzioni, D. P. Ankerst, N. S. Weiss, L. Y. T. Inoue, and I. M. Thompson Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence J Natl Cancer Inst, October 17, 2007; 99(20): 1510 - 1515. [Abstract] [Full Text] [PDF]

				K. Fall, H. Garmo, O. Andren, A. Bill-Axelson, J. Adolfsson, H.-O. Adami, J.-E. Johansson, and L. Holmberg Prostate-Specific Antigen Levels as a Predictor of Lethal Prostate Cancer J Natl Cancer Inst, April 4, 2007; 99(7): 526 - 532. [Abstract] [Full Text] [PDF]

				S. F. Slovin, A. S. Wilton, G. Heller, and H. I. Scher Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy Clin. Cancer Res., December 15, 2005; 11(24): 8669 - 8673. [Abstract] [Full Text] [PDF]

				H. I. Scher, M. Eisenberger, A. V. D'Amico, S. Halabi, E. J. Small, M. Morris, M. W. Kattan, M. Roach, P. Kantoff, K. J. Pienta, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group J. Clin. Oncol., February 1, 2004; 22(3): 537 - 556. [Abstract] [Full Text] [PDF]

				C. A. Carter, T. Donahue, L. Sun, H. Wu, D. G. McLeod, C. Amling, R. Lance, J. Foley, W. Sexton, L. Kusuda, et al. Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen Era J. Clin. Oncol., November 1, 2003; 21(21): 4001 - 4008. [Abstract] [Full Text] [PDF]

				J. A. Eastham, E. Riedel, P. T. Scardino, M. Shike, M. Fleisher, A. Schatzkin, E. Lanza, L. Latkany, and C. B. Begg Variation of Serum Prostate-Specific Antigen Levels: An Evaluation of Year-to-Year Fluctuations JAMA, May 28, 2003; 289(20): 2695 - 2700. [Abstract] [Full Text] [PDF]

				S. P. Balk, Y.-J. Ko, and G. J. Bubley Biology of Prostate-Specific Antigen J. Clin. Oncol., January 15, 2003; 21(2): 383 - 391. [Abstract] [Full Text] [PDF]

				T. Tanaka, T. Isono, T. Yoshiki, T. Yuasa, and Y. Okada A Novel Form of Prostate-specific Antigen Transcript Produced by Alternative Splicing Cancer Res., January 1, 2000; 60(1): 56 - 59. [Abstract] [Full Text]

				J.-M. Bidart, F. Thuillier, C. Augereau, J. Chalas, A. Daver, N. Jacob, F. Labrousse, and H. Voitot Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical Monitoring Clin. Chem., October 1, 1999; 45(10): 1695 - 1707. [Abstract] [Full Text] [PDF]

				U.-H. Stenman New Ultrasensitive Assays Facilitate Studies on the Role of Human Glandular Kallikrein (hK2) as a Marker for Prostatic Disease Clin. Chem., June 1, 1999; 45(6): 753 - 754. [Full Text] [PDF]